(Q33362473)

26 July 2017

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis (English)

1 reference

26 July 2017

0 references

Peter Rieckmann

1

1 reference

26 July 2017

Paul O'Connor

2

1 reference

26 July 2017

Gordon S Francis

3

1 reference

26 July 2017

Graham Wetherill

4

1 reference

26 July 2017

Enrica Alteri

5

1 reference

26 July 2017

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

27

1 reference

26 July 2017

10

1 reference

26 July 2017

745-756

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00005

26 July 2017

0 references

cites work

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

1 reference

12 December 2020

Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C

1 reference

12 December 2020

Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C

1 reference

12 December 2020

Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis.

1 reference

12 December 2020

Multiple sclerosis: side effects of interferon beta therapy and their management

1 reference

12 December 2020

Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease

1 reference

12 December 2020

Alpha-interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura

1 reference

12 December 2020

Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Treatment of hepatitis C related thrombocytopenia with interferon alpha

1 reference

12 December 2020

Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment

1 reference

12 December 2020

Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.

1 reference

12 December 2020

Interferon-alpha therapy in idiopathic thrombocytopenic purpura.

1 reference

12 December 2020

Treatment of hepatitis C virus-associated thrombocytopenic purpura with a combination of interferon alfa-2b and ribavirin

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

1 reference

12 December 2020

Recombinant human interferon alpha-2a therapy in children with chronic immune thrombocytopenic purpura

1 reference

12 December 2020

Aplastic anemia associated with interferon beta-1a

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia

1 reference

12 December 2020

Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis

1 reference

12 December 2020

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

1 reference

12 December 2020

Clinical toxicity of the interferons.

1 reference

12 December 2020

Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-alpha

1 reference

12 December 2020

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

10.2165/00002018-200427100-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference